LJN 452

Drug Profile

LJN 452

Alternative Names: LJN452

Latest Information Update: 20 Apr 2017

Price : $50

At a glance

  • Originator Novartis
  • Class Anti-inflammatories; Antifibrotics
  • Mechanism of Action Farnesoid X-activated receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-alcoholic steatohepatitis; Primary bile acid malabsorption; Primary biliary cirrhosis

Most Recent Events

  • 18 Apr 2017 Allergan in collaboration with Novartis plans a phase IIb trial for Non-alcoholic steatohepatitis (Combination therapy)
  • 05 Apr 2017 Novartis plans regulatory filings for Non-alcoholic steatohepatitis in 2021
  • 22 Dec 2016 LJN 452 receives Fast Track designation for Non-alcoholic steatohepatitis [PO,Capsule] in USA before December 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top